Cargando…
FEM-PrEP: Adherence Patterns and Factors Associated With Adherence to a Daily Oral Study Product for Pre-exposure Prophylaxis
BACKGROUND: Several clinical trials have demonstrated the safety and effectiveness of oral tenofovir disoproxil fumarate (TDF), with or without emtricitabine (FTC), as pre-exposure prophylaxis (PrEP) for reducing the risk of HIV acquisition. Adherence to the study product was insufficient to demonst...
Autores principales: | Corneli, Amy L., Deese, Jennifer, Wang, Meng, Taylor, Doug, Ahmed, Khatija, Agot, Kawango, Lombaard, Johan, Manongi, Rachel, Kapiga, Saidi, Kashuba, Angela, Van Damme, Lut |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
JAIDS Journal of Acquired Immune Deficiency Syndromes
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059551/ https://www.ncbi.nlm.nih.gov/pubmed/25157647 http://dx.doi.org/10.1097/QAI.0000000000000158 |
Ejemplares similares
-
Facilitators of Adherence to the Study Pill in the FEM-PrEP Clinical Trial
por: Corneli, Amy, et al.
Publicado: (2015) -
Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials
por: Agot, Kawango, et al.
Publicado: (2014) -
The Sexual Risk Context among the FEM-PrEP Study Population in Bondo, Kenya and Pretoria, South Africa
por: Headley, Jennifer, et al.
Publicado: (2014) -
A descriptive analysis of perceptions of HIV risk and worry about acquiring HIV among FEM-PrEP participants who seroconverted in Bondo, Kenya, and Pretoria, South Africa
por: Corneli, Amy L, et al.
Publicado: (2014) -
Hepatitis B virus reactivation or reinfection in a FEM-PrEP participant: a case report
por: Malahleha, Mookho, et al.
Publicado: (2015)